The progressive cost of complications in type 2 diabetes mellitus

Archives of Internal Medicine

Volumn 159, Issue 16, 1999, Pages 1873-1880

  Brown, Jonathan B ^a   Pedula, Kathryn L ^a   Bakst, Alan W ^b  

^a KAISER PERMANENTE   (United States)

^b SmithKlinc Beecham Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COST CONTROL; COST OF ILLNESS; DIABETIC NEPHROPATHY; FEMALE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OREGON; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 0033552080     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.16.1873     Document Type: Article

References (19)

1. Huse DM, Oster G, Killen AR, Lacy MJ, Colditz GA. The economic cost of non-insulin-dependent diabetes mellitus. JAMA. 1989;262:2708-2713.
2. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20:1396-1402.
3. Glauber H, Brown JB. Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol. 1994;47:1133-1142.
4. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996;39:1345-1350.
5. Bonora E, Willeit J, Kiechl S, et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population: the Bruneck Study. Diabetes Care. 1998;21:221-230.
6. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53: 1343-1347.
7. Greenlick M, Freeborn D, Pope C. Health Care Research in an HMO: Two Decades of Discovery. Baltimore, Md: Johns Hopkins University Press; 1998.
8. Hornbrook MC, Goodman MJ. Adjusting health benefit contributions to reflect risk. In: Hornbrook MC, ed. Advances in Health Economics and Health Services Research. Greenwich, Conn: JAI Press Inc; 1991:41-76.
9. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1413-1418.
10. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91: 831-837.
11. Glauber H, Brown J. Use of HMO pharmacy databases to study the quality of care and resource use in diabetes mellitus. Diabetes Care. 1992;15:870-876.
12. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.
13. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 1998; 1122-1128.
14. Barrett-Conner E, Khaw K. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol. 1988;128:116-123.
15. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317:1237-1245.
16. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351: 1755-1762.
17. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandanavian Simvastatin Suvival Study (4S). Diabetes Care. 1997;20:614-620.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-851.
19. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-713.